Sonoma Pharmaceuticals, Inc.

SNOA

US83558L2043

Pharmaceuticals

Delayed Nasdaq Other stock markets 07:12:33 06/06/2024 pm IST			5-day change	1st Jan Change
0.1914 ^USD	+0.76%		-8.68%	+3.77%

09/05	Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores	CI
08/02	Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Sonoma Pharmaceuticals, Inc. Names Marc Umscheid Chief Operating Officer

May 08, 2018 at 04:30 pm IST

Sonoma Pharmaceuticals, Inc. announced that Marc Umscheid has been promoted to chief operating officer effective immediately.

Latest news about Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores	09/05	CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09/02	CI
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use	23/01	CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network	09/01	CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14/11	CI
Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference	03/11	CI
Sector Update: Health Care Stocks Ease in Late Afternoon	27/23/27	MT
Sector Update: Health Care	27/23/27	MT
Top MIdday Decliners	27/23/27	MT
Wall Street Set to Open Lower as GDP, Jobless Claims Higher Than Expected	26/23/26	MT
Ladenburg Thalmann Initiates Coverage on Sonoma Pharmaceuticals at Buy, $3.25 Price Target	05/23/05	MT
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced	15/23/15	CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board	03/23/03	CI
Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller	15/23/15	CI
Earnings Flash (SNOA) SONOMA PHARMACEUTICALS Reports Q4 Revenue $3M	22/23/22	MT
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	22/23/22	CI
Sonoma Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	21/23/21	CI
Top Premarket Gainers	09/23/09	MT
Sonoma Pharmaceuticals, Inc. Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union	09/23/09	CI
Sonoma Pharmaceuticals, Inc. Announces CFO Changes	14/23/14	CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	15/23/15	CI
Sonoma Pharmaceuticals Signs Distribution Deal With Daewoong Pharmaceutical to Sell Skin Products in South Korea	31/23/31	MT
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea	31/23/31	CI
Sector Update: Health Care Stocks Largely Sit Out Late Market Rebound	26/23/26	MT

Chart Sonoma Pharmaceuticals, Inc.

Duration

Period

More charts

Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care, Microcyn, Ocucyn Eyelid and Eyelash Cleanser, Microdacyn60 Oral Care, Podiacyn Advanced Everyday Foot Care, and MicrocynAH. Regenacyn Advanced Scar Gel helps to improve the overall appearance of scars while reducing pain, itch, redness, and inflammation. Regenacyn Plus is a prescription-strength scar gel which is available as an office dispense product through dermatology practices and medical spas. Pediacyn is a pediatric dermatology and wound care product for over-the-counter use. MicrocynAH is a HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.

Sector

Pharmaceuticals

Calendar

10/07/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.19

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SONOMA PHARMACEUTICALS, INC.	+3.77%	2.97M
ELI LILLY AND COMPANY	+43.55%	749B
NOVO NORDISK A/S	+38.91%	605B
JOHNSON & JOHNSON	-7.48%	351B
MERCK & CO., INC.	+18.76%	328B
ABBVIE INC.	+6.84%	292B
NOVARTIS AG	+11.26%	216B
ROCHE HOLDING AG	-2.82%	214B
PFIZER, INC.	+1.67%	167B
AMGEN INC.	+6.18%	165B

Other Pharmaceuticals